Browsing by Author "Isakson, Brant E."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Connexin 43 Across the Vasculature: Gap Junctions and Beyond
    Sedovy, Meghan W.; Leng, Xinyan; Leaf, Melissa R.; Iqbal, Farwah; Payne, Laura Beth; Chappell, John C.; Johnstone, Scott R. (Karger Publishers, 2022-10-03)
    Connexin 43 (Cx43) is essential to the function of the vasculature. Cx43 proteins form gap junctions that allow for the exchange of ions and molecules between vascular cells to facilitate cell-to-cell signaling and coordinate vasomotor activity. Cx43 also has intracellular signaling functions that influence vascular cell proliferation and migration. Cx43 is expressed in all vascular cell types, although its expression and function vary by vessel size and location. This includes expression in vascular smooth muscle cells (vSMC), endothelial cells (EC), and pericytes. Cx43 is thought to coordinate homocellular signaling within EC and vSMC. Cx43 gap junctions also function as conduits between different cell types (heterocellular signaling), between EC and vSMC at the myoendothelial junction, and between pericyte and EC in capillaries. Alterations in Cx43 expression, localization, and post-translational modification have been identified in vascular disease states, including atherosclerosis, hypertension, and diabetes. In this review, we discuss the current understanding of Cx43 localization and function in healthy and diseased blood vessels across all vascular beds.
  • Thumbnail Image
    Mechanisms of Connexin Regulating Peptides
    King, D. Ryan; Sedovy, Meghan W.; Leng, Xinyan; Xue, Jianxiang; Lamouille, Samy Y.; Koval, Michael; Isakson, Brant E.; Johnstone, Scott R. (MDPI, 2021-09-22)
    Gap junctions (GJ) and connexins play integral roles in cellular physiology and have been found to be involved in multiple pathophysiological states from cancer to cardiovascular disease. Studies over the last 60 years have demonstrated the utility of altering GJ signaling pathways in experimental models, which has led to them being attractive targets for therapeutic intervention. A number of different mechanisms have been proposed to regulate GJ signaling, including channel blocking, enhancing channel open state, and disrupting protein-protein interactions. The primary mechanism for this has been through the design of numerous peptides as therapeutics, that are either currently in early development or are in various stages of clinical trials. Despite over 25 years of research into connexin targeting peptides, the overall mechanisms of action are still poorly understood. In this overview, we discuss published connexin targeting peptides, their reported mechanisms of action, and the potential for these molecules in the treatment of disease.